Cargando…

Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT

RATIONALE: There is an association between body mass index (BMI) and mortality in chronic obstructive pulmonary disease (COPD), with underweight individuals having higher mortality risk. Mortality and exacerbation risks among individuals with higher BMI are unclear. OBJECTIVES: To examine the relati...

Descripción completa

Detalles Bibliográficos
Autores principales: Putcha, Nirupama, Anzueto, Antonio R., Calverley, Peter M. A., Celli, Bartolomé R., Tashkin, Donald P., Metzdorf, Norbert, Mueller, Achim, Wise, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867355/
https://www.ncbi.nlm.nih.gov/pubmed/34406915
http://dx.doi.org/10.1513/AnnalsATS.202006-722OC
_version_ 1784656038769721344
author Putcha, Nirupama
Anzueto, Antonio R.
Calverley, Peter M. A.
Celli, Bartolomé R.
Tashkin, Donald P.
Metzdorf, Norbert
Mueller, Achim
Wise, Robert A.
author_facet Putcha, Nirupama
Anzueto, Antonio R.
Calverley, Peter M. A.
Celli, Bartolomé R.
Tashkin, Donald P.
Metzdorf, Norbert
Mueller, Achim
Wise, Robert A.
author_sort Putcha, Nirupama
collection PubMed
description RATIONALE: There is an association between body mass index (BMI) and mortality in chronic obstructive pulmonary disease (COPD), with underweight individuals having higher mortality risk. Mortality and exacerbation risks among individuals with higher BMI are unclear. OBJECTIVES: To examine the relationship between BMI and adverse outcomes in COPD. METHODS: This post hoc analysis included data from TIOSPIR (Tiotropium Safety and Performance in Respimat) (N = 17,116) and tiotropium-treated patients in UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) (N = 2,986). BMI classes (underweight [BMI < 20 kg/m(2)], normal weight [BMI 20 to <25 kg/m(2)], overweight [BMI 25 to <30 kg/m(2)], obesity class I [BMI 30 to <35 kg/m(2)], obesity class II [BMI 35 to <40 kg/m(2)], and obesity class III [BMI ⩾ 40 kg/m(2)]) were examined for adjusted associations with mortality, exacerbation, and nonfatal cardiovascular event risk using over 50,000 patient-years of cumulative follow-up data. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox regression models. RESULTS: In TIOSPIR, obesity prevalence was 22%, overweight 32%, and underweight 12%. The proportion of females was highest in obesity classes II and III. Overweight and obese participants had better baseline lung function versus other BMI classes; underweight participants were more likely to be current smokers. Underweight participants had a significantly higher risk of death (HR, 1.88; 95% CI, 1.62–2.20; P < 0.0001) and severe exacerbations (HR, 1.31; 95% CI, 1.16–1.47; P < 0.0001) versus normal-weight participants; however, overweight and obese participants were at lower to no additional risk. Results from UPLIFT were similar to TIOSPIR. CONCLUSIONS: These results suggest that there is a strong association between body weight, COPD events, and risk of death. A holistic management approach taking into account respiratory and cardiovascular risk factors and nutritional status is needed to improve the general well-being of patients with COPD.
format Online
Article
Text
id pubmed-8867355
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Thoracic Society
record_format MEDLINE/PubMed
spelling pubmed-88673552022-02-24 Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT Putcha, Nirupama Anzueto, Antonio R. Calverley, Peter M. A. Celli, Bartolomé R. Tashkin, Donald P. Metzdorf, Norbert Mueller, Achim Wise, Robert A. Ann Am Thorac Soc Original Research RATIONALE: There is an association between body mass index (BMI) and mortality in chronic obstructive pulmonary disease (COPD), with underweight individuals having higher mortality risk. Mortality and exacerbation risks among individuals with higher BMI are unclear. OBJECTIVES: To examine the relationship between BMI and adverse outcomes in COPD. METHODS: This post hoc analysis included data from TIOSPIR (Tiotropium Safety and Performance in Respimat) (N = 17,116) and tiotropium-treated patients in UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) (N = 2,986). BMI classes (underweight [BMI < 20 kg/m(2)], normal weight [BMI 20 to <25 kg/m(2)], overweight [BMI 25 to <30 kg/m(2)], obesity class I [BMI 30 to <35 kg/m(2)], obesity class II [BMI 35 to <40 kg/m(2)], and obesity class III [BMI ⩾ 40 kg/m(2)]) were examined for adjusted associations with mortality, exacerbation, and nonfatal cardiovascular event risk using over 50,000 patient-years of cumulative follow-up data. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox regression models. RESULTS: In TIOSPIR, obesity prevalence was 22%, overweight 32%, and underweight 12%. The proportion of females was highest in obesity classes II and III. Overweight and obese participants had better baseline lung function versus other BMI classes; underweight participants were more likely to be current smokers. Underweight participants had a significantly higher risk of death (HR, 1.88; 95% CI, 1.62–2.20; P < 0.0001) and severe exacerbations (HR, 1.31; 95% CI, 1.16–1.47; P < 0.0001) versus normal-weight participants; however, overweight and obese participants were at lower to no additional risk. Results from UPLIFT were similar to TIOSPIR. CONCLUSIONS: These results suggest that there is a strong association between body weight, COPD events, and risk of death. A holistic management approach taking into account respiratory and cardiovascular risk factors and nutritional status is needed to improve the general well-being of patients with COPD. American Thoracic Society 2022-02-01 /pmc/articles/PMC8867355/ /pubmed/34406915 http://dx.doi.org/10.1513/AnnalsATS.202006-722OC Text en Copyright © 2022 by the American Thoracic Society https://creativecommons.org/licenses/by-nc-nd/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org).
spellingShingle Original Research
Putcha, Nirupama
Anzueto, Antonio R.
Calverley, Peter M. A.
Celli, Bartolomé R.
Tashkin, Donald P.
Metzdorf, Norbert
Mueller, Achim
Wise, Robert A.
Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
title Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
title_full Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
title_fullStr Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
title_full_unstemmed Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
title_short Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
title_sort mortality and exacerbation risk by body mass index in patients with copd in tiospir and uplift
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867355/
https://www.ncbi.nlm.nih.gov/pubmed/34406915
http://dx.doi.org/10.1513/AnnalsATS.202006-722OC
work_keys_str_mv AT putchanirupama mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift
AT anzuetoantonior mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift
AT calverleypeterma mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift
AT cellibartolomer mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift
AT tashkindonaldp mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift
AT metzdorfnorbert mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift
AT muellerachim mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift
AT wiseroberta mortalityandexacerbationriskbybodymassindexinpatientswithcopdintiospiranduplift